Clinical Trial

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Study acronym: SCOTI
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-04-07; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2023-05-04
Trial Details
NCT Number NCT05806931
Lead Sponsor Rutgers, The State University of New Jersey
Conditions Colon Cancer, Rectal Cancer
Enrollment 50 participants
Start Date 2023-05-17
Primary Completion 2026-05-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-18